Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
76 hedge funds and large institutions have $143M invested in Avadel Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
90% more capital invested
Capital invested by funds: $75.5M → $143M (+$67.7M)
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
4% less ownership
Funds ownership: 57.15% → 53.16% (-4%)
7% less funds holding
Funds holding: 82 → 76 (-6)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
38% less call options, than puts
Call options by funds: $5.54M | Put options by funds: $8.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
+$2.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.86M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.22M |
| 4 |
DMKJ
David M. Knott Jr
|
+$920K |
| 5 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$677K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$8.19M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$5.13M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$3.87M |
| 4 |
Two Sigma Investments
New York
|
-$1.34M |
| 5 |
Millennium Management
New York
|
-$519K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Millennium Management
New York
| – | -$519K | -212,590 | Closed |
|
|
JF
77
Jump Financial
Chicago,
Illinois
| – | -$137K | -56,300 | Closed |
|
|
RJA
78
Raymond James & Associates
St Petersburg,
Florida
| – | -$83K | -34,141 | Closed |
|
79
Jane Street
New York
| – | -$81K | -33,220 | Closed |
|
|
IAM
80
Iridian Asset Management
Westport,
Connecticut
| – | -$73K | -30,000 | Closed |
|
|
ACM
81
Aquatic Capital Management
Chicago,
Illinois
| – | -$65K | -26,600 | Closed |
|
|
XT
82
XTX Topco
George Town,
Cayman Islands
| – | -$32K | -13,093 | Closed |
|
83
Marshall Wace
London,
United Kingdom
| – | -$27K | -11,081 | Closed |
|
84
BNP Paribas Financial Markets
Paris,
France
| – | -$8.05K | -3,298 | Closed |
|
|
CG
85
Cutler Group
San Francisco,
California
| – | -$3.84K | -698 | Closed |
|
86
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$1K | -500 | Closed |
|
87
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -344 | Closed |
|
|
IBT
88
International Biotechnology Trust
London,
United Kingdom
| – | -$50K | -122 | Closed |
|
AVDL Hedge Fund Activity: Q3 2022 in Review
76 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2022, worth a combined $143M — up 90% from $75.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AVDL and 10 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was Gendell Jeffrey L, adding an estimated $2.9M. The largest seller was Woodline Partners, cutting an estimated $8.19M.
- 76 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2022, down from 82 in Q2 2022.
- Funds reported $143M of Avadel Pharmaceuticals stock for Q3 2022, up 90% quarter-over-quarter.
- 10 funds opened new Avadel Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of -4 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2022 was Gendell Jeffrey L, an estimated $2.9M added.
- The largest Avadel Pharmaceuticals seller in Q3 2022 was Woodline Partners, an estimated $8.19M sold.
Based on aggregated 13F filings for Q3 2022.